Eli Lilly and Company
LLY
NYSE
12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Revenue | 28.10% | 36.84% | 28.11% | -10.88% | -8.73% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 28.10% | 36.84% | 28.11% | -10.88% | -8.73% |
Cost of Revenue | 15.50% | 17.79% | 26.35% | -21.50% | -27.85% |
Gross Profit | 31.49% | 42.44% | 28.61% | -7.05% | -1.72% |
SG&A Expenses | 16.73% | 10.95% | 18.23% | 11.53% | 2.03% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 20.93% | 21.49% | 25.94% | 1.91% | -8.43% |
Operating Income | 44.65% | 73.77% | 34.02% | -35.61% | -9.40% |
Income Before Tax | 19.67% | -72.71% | 91.48% | -25.51% | 13.94% |
Income Tax Expenses | 101.07% | 325.83% | 135.33% | 22.63% | 39.46% |
Earnings from Continuing Operations | 13.01% | -103.95% | 85.11% | -29.32% | 12.26% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 13.01% | -103.95% | 85.11% | -29.32% | 12.26% |
EBIT | 44.65% | 73.77% | 34.02% | -35.61% | -9.40% |
EBITDA | 38.66% | 64.62% | 29.18% | -32.97% | -10.40% |
EPS Basic | 13.10% | -103.96% | 85.24% | -29.11% | 12.86% |
Normalized Basic EPS | 45.46% | 77.17% | 36.49% | -37.48% | -10.54% |
EPS Diluted | 13.01% | -103.96% | 85.71% | -29.05% | 12.99% |
Normalized Diluted EPS | 45.46% | 77.79% | 36.43% | -37.46% | -10.54% |
Average Basic Shares Outstanding | -0.08% | -0.10% | -0.07% | -0.30% | -0.53% |
Average Diluted Shares Outstanding | -0.08% | -0.44% | -0.02% | -0.34% | -0.53% |
Dividend Per Share | 15.31% | 15.31% | 15.31% | 15.31% | 15.29% |
Payout Ratio | 0.02% | -30.13% | -0.38% | 0.63% | 0.02% |